Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of ibrutinib versus placebo in previously untreated high-risk Binet stage A chronic lymphocytic leukemia
2013-003211-22Phase 3Completed
- Sponsor
- University of Cologne
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Ibrutinib, Placebo and Non-randomized low-risk observation or reference arm (3 arms). Primary endpoint: Event-free survival. Started Feb 2014; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2013-003211-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003211-22.